债券代码：123065 债券简称：宝莱转债 广东宝莱特医用科技股份有限公司 证券代码：300246 证券简称：宝莱特 公告编号：2023-061 关于宝莱转债 2023 年付息的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 6、"宝莱转债"本次付息的债权登记日为 2023 年 9 月 1 日，截止至 2023 年 9 月 1 日下午深圳证券交易所收市后，在中国证券登记结算有限责任公司深圳分公 司（以下简称"中国结算深圳分公司"）登记在册的"宝莱转债"持有人享有本次派 发的利息，在 2023 年 9 月 1 日前（含当日）申请转换成公司股票的可转换公司 债券，公司不再向其持有人支付本计息年度及以后计息年度的利息。 特别提示： 1、"宝莱转债"（债券代码：123065）将于 2023 年 9 月 4 日支付第三年利息， 每 10 张"宝莱转债"（面值 1,000 元）利息为 10.00 元（含税）。 2、债权登记日：2023 年 9 月 1 日 3、除息日：2023 年 9 月 4 日 4、付息日：2023 年 9 月 4 日 5、本次付息期间及票面利率：计息 ...

本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 特别提示 1.案件所处的诉讼阶段：收到法院诉讼材料，尚未开庭。 2.上市公司所处当事人地位：被告。 3.涉案的金额：案件一 1,000 万元、案件二 1,000 万元、案件三 1,000 万元。 债券代码：123065 债券简称：宝莱转债 证券代码：300246 证券简称：宝莱特 公告编号：2023-057 广东宝莱特医用科技股份有限公司 关于涉及诉讼的公告 债券代码：123065 债券简称：宝莱转债 4.对上市公司损益产生的影响：案件尚未开庭审理，对公司本期利润或期后 利润的影响存在不确定性。 广东宝莱特医用科技股份有限公司（以下简称"公司"或"宝莱特公司"）于 近日收到福建省福州市中级人民法院送达的传票及《民事起诉状》｛（2023）闽 01 民初 936 号、（2023）闽 01 民初 937 号、（2023）闽 01 民初 938 号｝等法 律文书，截至本公告披露日，该案件已立案受理尚未开庭审理。 一、诉讼的基本情况 案件一：案号为（2023）闽 01 民初 936 号 原告：深圳迈瑞生物医疗电子股份有限公司（ ...

证券代码：300246 证券简称：宝莱特 广东宝莱特医用科技股份有限公司投资者关系活动记录表 编号：20230701 特定对象调研 分析师会议 投资者关系活 媒体采访 业绩说明会 动类别 新闻发布会 路演活动 现场参观 其他 时间 2023 年 7 月 28 日、2023 年 7 月 31 日 地点 进门财经、腾讯会议 参与单位名称 光大证券、申万宏源证券、上海证券、华鑫证券等 85 家机构（详情见附 后的参会名单） 上市公司接待 董事会秘书兼副总裁杨永兴先生，财务总监许薇女士，证券事务代表李韵 人员姓名 妮女士，证券事务专员钟欣昊先生。 公司介绍环节： 投资者关系活 宝莱特成立于 1993 年，主营业务为医疗器械产品的研发、生产、销 动主要内容介 售，主要涵盖健康监测与血液净化两大业务板块。公司作为中国最早一批 绍 研发制造医疗监护仪的民族企业，是监护仪产品线最完善的公司之一，是 国家发改委授予的"国家多参数监护仪产业化基地"，目前公司的监护设备 已覆盖数千家医疗机构。 公司监护类产品品类丰富，拥有一体式监护仪、插件式监护仪和掌上 监护仪三大系列产品，涵盖了急危重症监护、亚重症监护、手术麻醉监护、 新生儿及 ...

Financial Performance - The company's operating revenue for the first half of 2023 was approximately ¥665.23 million, representing a 19.22% increase compared to ¥557.99 million in the same period last year[22]. - Net profit attributable to shareholders reached approximately ¥58.86 million, a significant increase of 728.20% from ¥7.11 million in the previous year[22]. - The net profit after deducting non-recurring gains and losses was approximately ¥44.40 million, up 1,072.95% from ¥3.79 million year-on-year[22]. - Basic earnings per share increased to ¥0.3091, reflecting a 639.47% rise compared to ¥0.0418 in the same period last year[22]. - Total assets at the end of the reporting period were approximately ¥2.62 billion, an increase of 7.34% from ¥2.44 billion at the end of the previous year[22]. - The company's cash flow from operating activities showed a net outflow of approximately ¥4.12 million, a decline of 106.42% compared to a net inflow of ¥64.15 million in the same period last year[22]. - The weighted average return on net assets was 4.08%, up from 0.53% in the previous year[22]. - The gross margin for the first half of 2023 improved to 45%, up from 40% in the same period last year[68]. Market Outlook - The medical device market in China is projected to reach approximately ¥1.5 trillion by 2025, with a compound annual growth rate of 20.04% from 2015 to 2020[36]. - The global medical device market is expected to reach about $595 billion by 2024, with a compound annual growth rate of 5.64%[35]. - The blood purification industry is projected to grow steadily, with the global dialysis market size increasing from €66.8 billion in 2015 to €82 billion in 2020, reflecting an annual growth rate of approximately 4%[39]. - The company anticipates continued growth in medical demand due to an aging population and increasing health awareness among the public[37]. - The market for hemodialysis equipment and consumables in China is projected to grow from 13.4 billion RMB in 2021 to 28.1 billion RMB by 2026, representing a compound annual growth rate of 18.6%[40]. Product Development and Innovation - The company emphasizes a strong focus on R&D, implementing a collaborative development process to ensure the conversion of technological innovations into results[32]. - The company launched several new products, including peritoneal dialysis equipment and electronic urine volume meters, focusing on smart monitoring solutions[52]. - The PD600 peritoneal dialysis device received its medical device registration certificate, featuring IoT capabilities for remote monitoring[53]. - The company added 45 new patents during the reporting period, including 5 invention patents, strengthening its innovation capabilities[55]. - The company is focusing on high-end product development and expanding its market presence in response to domestic medical device replacement opportunities[52]. Strategic Initiatives - The company operates primarily through a buyout distribution model domestically, enhancing brand influence while reducing market costs[31]. - The company maintains a centralized procurement model, leveraging a few high-quality suppliers to achieve significant price advantages[33]. - The company has established nine consumable bases and three channel platforms, positioning itself strongly in the blood purification market[46]. - The company is expanding its production capacity in Zhuhai and Suzhou, aiming to enhance its competitive edge in the blood purification industry[46]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market presence[68]. Risk Management - The company has highlighted potential risks and countermeasures in its report, emphasizing the importance of investor awareness regarding investment risks[3]. - The company is facing risks from national medical policy changes, particularly regarding blood dialysis and high-value medical consumables, which could impact revenue if alternative treatments receive more support[119]. - Rising raw material costs present a significant risk to profitability, prompting the company to invest in supply chain integration to control costs effectively[124]. - The competitive landscape in the blood dialysis market is intensifying, which may lead to price reductions and lower profit margins, posing risks to future profitability[122]. Corporate Governance and Social Responsibility - The company plans not to distribute cash dividends or issue bonus shares for this reporting period[4]. - The company donated medical equipment to earthquake relief efforts in Turkey and has contributed over 8 million yuan to various charitable organizations[62]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[141]. - The company adheres to the ISO14001-2015 environmental management system standards to reduce emissions and energy consumption[141]. Shareholder Information - The total share capital increased from 174,814,904 shares to 175,680,734 shares following the stock incentive plan[136]. - The company has not disclosed any special voting rights or pledged shares among the top shareholders[182]. - The report indicates no changes in the number of shares held by major shareholders during the reporting period[182]. - The company maintains a diverse shareholder base, including both individual and institutional investors[182].

Group 1: Company Overview - Guangdong Baolait Medical Technology Co., Ltd. was established in 1993, focusing on the R&D, production, and sales of medical devices, primarily in life information and support as well as nephrology sectors [1] - The company is recognized as one of the earliest domestic manufacturers of medical monitors and has a comprehensive product line in this category, covering thousands of medical institutions [1][2] Group 2: Product Range - The company offers three major series of monitors, including critical care, sub-critical care, anesthesia monitoring, and neonatal care, applicable in various medical settings such as general wards, emergency rooms, ICUs, and operating rooms [2] - In the home healthcare sector, Baolait provides wearable medical products like pulse oximeters, ultrasound Doppler fetal heart monitors, temperature monitoring systems, and blood pressure monitors [2] Group 3: Financial Performance - In 2022, the company achieved a revenue of 1,183.70 million CNY, a year-on-year increase of 8.49%, with the blood purification segment contributing 787.14 million CNY, up by 16.77% [2] - For Q1 2023, the company reported a revenue of 344.57 million CNY, reflecting an 18.09% year-on-year growth, and a net profit of 27.16 million CNY, which is a significant increase of 94.75% [2] Group 4: Market Trends and Opportunities - The demand for medical monitoring equipment is expected to grow due to the increasing healthcare infrastructure needs and the rising number of medical institutions in China [3] - The domestic blood dialysis market presents significant opportunities for local brands, especially in dialysis equipment, as imported products no longer dominate the market [4] Group 5: R&D and Innovation - The company emphasizes innovation, holding 68 medical device registration certificates and 45 invention patents as of December 31, 2022 [2] - In 2022, R&D investment reached 90.63 million CNY, a 17.04% increase, with plans for steady growth in future R&D expenditures to support ongoing development [5]

Financial Performance - In 2022, the company achieved operating revenue of 118,369.97 million, a year-on-year increase of 8.49% [1] - The blood purification segment generated sales revenue of 78,713.70 million, growing by 16.77% [1] - The net profit attributable to shareholders decreased due to rising logistics costs, raw material prices, and increased sales and R&D expenses [1] - In 2022, total sales expenses reached 16,346.89 million, up 42.78% year-on-year; R&D expenses amounted to 8,754.33 million, increasing by 17.77% [2] 2023 Outlook - In Q1 2023, the company reported operating revenue of 34,456.58 million, an 18.09% increase year-on-year, and a net profit of 2,716.22 million, up 94.75% [2] - The company aims to focus on health monitoring and blood purification, targeting significant sales breakthroughs in peritoneal dialysis equipment and consumables [2] - The goal is to double the sales volume of dialysis devices and related products annually [2] Product Development and Market Strategy - The company offers a range of monitoring products, including integrated and modular monitors, widely used in various medical settings [2] - In the blood purification sector, the company has developed advanced dialysis machines and consumables, with a focus on domestic market growth and replacing imported products [3][4] - The D800Plus dialysis machine is noted for its innovative three-pump design, enhancing treatment effectiveness [3] Market Opportunities - The domestic blood dialysis market presents significant opportunities for local manufacturers, with less than 10% market share for fully domestic dialysis equipment [4] - The trend towards home-based automated peritoneal dialysis is expected to grow, supported by government policies and increasing patient adoption [4][5] Regional Production and Expansion - The company has established production bases for dialysis consumables across multiple regions, including Suzhou and Zhuhai, to enhance market reach and reduce transportation costs [5] - Recent acquisitions have strengthened the company's presence in the northwest region, with plans to expand production capacity and market coverage [5]

证券代码：300246 证券简称：宝莱特 广东宝莱特医用科技股份有限公司投资者关系活动记录表 编号：20230601 投资者关系活 动类别 特定对象调研 分析师会议 媒体采访 业绩说明会 新闻发布会 路演活动 现场参观 其他 时间 2023 年 5 月 30 日、2023 年 6 月 1 日、2023 年 6 月 2 日 地点 腾讯会议 参与单位名称 （排名不分先 后） 国金证券：李润兰 中银证券：周海涛 上银基金：纪晓天 玄元投资：廖仕超 恒生前海：鲁娜 申万菱信：杨扬 盘京投资：温旭鸾 建投资管：彭国宇 中银基金：王方舟、郑宁 淳厚基金：严定安、张卓颖 银华基金：陈子浩、郭思捷、焦巍 金信基金：赵浩然、谭智汨 平安基金：王文豪、张淼、刘杰 上市公司接待 人员姓名 董事会秘书兼副总裁杨永兴先生，证券事务代表李韵妮女士，证券事务专 员钟欣昊先生。 投资者关系活 动主要内容介 绍 公司经营情况介绍： 2022 年，面对复杂多变的宏观环境与诸多的困难挑战，公司在坚持发 展战略的同时积极应对市场变化，聚焦于引进优秀人才、完善营销网络、 推广高端新品、优化研发力量，确保年度经营计划有序开展。 尽管公司遭遇各种不利因素 ...

证券代码：300246 证券简称：宝莱特 广东宝莱特医用科技股份有限公司投资者关系活动记录表 编号：20230502 特定对象调研 分析师会议 投资者关系活 媒体采访 业绩说明会 动类别 新闻发布会 路演活动 现场参观 其他 时间 2023 年 5 月 23 至 2023 年 5 月 25 日 地点 珠海、上海、腾讯会议 参与单位名称 光大证券：张杰 博时基金：张涵 （排名不分先 安信基金：徐衍鹏 国联安基金：赵子淇 后） 平安资产：林启姜 天弘基金：郭相博 华安基金：于嘉轩 金鹰基金：张天问 华宝基金：易镜明、张金涛、薄玉、郑 中国人保资产：蔡春根、马善 英亮、齐震、 尧、华旭桥 农银汇理基金：凌晨、李蕾、梦圆 上市公司接待 人员姓名 董事会秘书兼副总裁杨永兴先生，证券事务专员钟欣昊先生。 公司经营情况介绍： 投资者关系活 2022 年，面对复杂多变的宏观环境与诸多的困难挑战，公司在坚持发 动主要内容介 展战略的同时积极应对市场变化，聚焦于引进优秀人才、完善营销网络、 绍 推广高端新品、优化研发力量，确保年度经营计划有序开展。 尽管公司遭遇各种不利因素影响，但通过多方努力，尤其是产品力的 | --- | | ...

广东宝莱特医用科技股份有限公司投资者关系活动记录表 编号：20230501 | |  特定对象调研 | | 分析师会议 | | | --- | --- | --- | --- | --- | | 投资者关系活 | 媒体采访 | | 业绩说明会 | | | 动类别 | 新闻发布会 | | 路演活动 | | | | 现场参观 | | | | | | 其他 | | | | | 时间 | 2023 年 5 月 10 | 日、2023 | 年 5 月 11 日 | | | 地点 | 上海、深圳 | | | | | 参与单位名称 | 申万宏源：陈烨远、陶涛、王林森 | | | 国盛证券：殷一凡 | | （排名不分先 | 世域投资：李巍 | | | 鼎锋资产：刘硕 | | 后） | 嘉实基金：孙晓晖 | | | 睿远基金：赵培森 | | | 汇添富基金：谢杰 | | | 健顺投资：王坚 | | | 仙人掌私募：熊龙启 | | | 宝弘景资产：张乐 | | | 磐耀资产：孙智超 | | | 新伯霖私募：何志俊 | | | 国鸣投资：李长天 | | | 安信资管：刘亚洲 | | | 富荣基金：杨皓童 | | | ...

广东宝莱特医用科技股份有限公司投资者关系活动记录表 编号：20230402 投资者关系活 动类别 特定对象调研 分析师会议 媒体采访 业绩说明会 新闻发布会 路演活动 现场参观 其他 时间 2023 年 4 月 28 日 地点 价值在线（https://www.ir-online.cn/） 参与单位名称 线上参与公司 2022 年度业绩网上说明会的全体投资者 上市公司接待 人员姓名 董事长兼总裁 燕金元先生 独立董事 杨振新先生 保荐代表人 胡凤兴先生 财务总监 许薇女士 董事会秘书兼副总裁 杨永兴先生 投资者关系活 动主要内容介 绍 1、请简单介绍一下公司去年及今年一季度的经营情况，谢谢！ 答：2022 年，面对复杂多变的宏观环境与诸多的困难挑战，在公司管 理层和全体员工的共同努力下，公司经营情况总体保持稳定，各项财务指 标较为健康：2022年，公司实现营业收入118,369.97万元，同比增长8.49%； 实现归属于上市公司股东的净利润为 2,199.80 万元，同比下降 65.52%。 2022 年公司净利润下降除了受物流成本上升、原材料价格上涨等负面影 响外，也是公司为保持持续竞争力，着眼未来进行战略 ...